Compare EOG Resources Inc (EOG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs Recursion Pharmaceuticals Inc — how do they compare? EOG Resources Inc trades at $139.3 (market cap $73.22B), while Recursion Pharmaceuticals Inc trades at $3.2 (market cap $1.75B). The key difference: EOG Resources Inc is far larger — about 41.8× Recursion Pharmaceuticals Inc's market cap, and EOG Resources Inc pays a 2.97% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| EOG | RXRX | |
|---|---|---|
Market Cap | $73.22B | $1.75B |
Sector | Energy | Health |
52-Week High | $149.89 | $6.79 |
52-Week Low | $101.78 | $2.84 |
Enterprise Value | $77.68B | $1.17B |
Dividend Yield | 2.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $138.01, down 1.15% on the day, with a bullish technical signal from moving averages and strong analyst support. The company maintains robust profitability with a net income margin of 23.39% and has beaten earnings estimates for the last three quarters. Recent news highlights its valuation discount and operational strength, with a consensus price target of $156.40 suggesting upside potential.
The outlook for EOG is positive, driven by consistent earnings beats, solid cash flow, and a favorable analyst consensus. Key risks include oil price volatility and elevated capital expenditures. The stock presents an opportunity for growth investors seeking exposure to a high-quality energy producer trading below target prices.
Recursion Pharmaceuticals (RXRX) trades at $3.175, down 4.94% on the day, reflecting ongoing investor concerns about profitability. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal significant losses with a net income margin of -851.51% despite recent earnings beats. Analyst consensus is mixed with 40% buy ratings but a $7.83 price target suggesting substantial upside potential from current levels.
The outlook remains speculative given the company's heavy losses and cash burn, though AI-driven drug discovery platform and recent clinical progress offer long-term potential. Key risks include prolonged unprofitability, intense biotech competition, and dependence on successful drug development. The stock presents high-risk/high-reward characteristics suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
